Upstream Bio (UPB) Common Equity (2023 - 2026)
Upstream Bio (UPB) posted quarterly Common Equity of $304.0 million for Q1 2026, down 31.78% year-over-year from $445.6 million in Q1 2025, and down 10.53% quarter-over-quarter from $339.8 million in Q4 2025.
Upstream Bio (UPB) Common Equity (2023 - 2026) Analysis & Trends
Upstream Bio's Common Equity history runs 4 years deep, the most recent figure standing at $304.0 million for Q1 2026.
- In Q1 2026, Common Equity fell 31.78% year-over-year to $304.0 million; the TTM figure through Mar 2026 stood at $304.0 million (down 31.78% YoY), while the FY2025 annual figure was $339.8 million, down 27.69% from the prior year.
- Common Equity for Q1 2026 stood at $304.0 million, down from $339.8 million in the prior quarter.
- The five-year high for Common Equity was $469.9 million in Q4 2024, with the low at -$160.3 million in Q3 2024.
- The 4-year median for Common Equity is $304.0 million (2026), against an average of $151.9 million.
- Peak annual rise in Common Equity reached 481.6% in 2024, while the deepest fall reached 42.87% in 2024.
- Upstream Bio's Common Equity stood at -$123.1 million in 2023, then soared by 481.6% to $469.9 million in 2024, then slipped by 27.69% to $339.8 million in 2025, then slipped by 10.53% to $304.0 million in 2026.
- Business Quant data shows UPB's Common Equity at $304.0 million in Q1 2026, $339.8 million in Q4 2025, and $378.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | 270.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 270.96 Mn |
| Mar 31, 2026 | 304.00 Mn |
| Dec 31, 2025 | 339.77 Mn |
| Sep 30, 2025 | 378.58 Mn |
| Jun 30, 2025 | 408.74 Mn |
| Mar 31, 2025 | 445.61 Mn |
| Dec 31, 2024 | 469.85 Mn |
| Sep 30, 2024 | -160.31 Mn |
| Jun 30, 2024 | -146.61 Mn |
| Mar 31, 2024 | -133.41 Mn |
| Dec 31, 2023 | -123.13 Mn |
| Sep 30, 2023 | -112.20 Mn |